SG10201913950XA - Liquid protein formulations containing viscosity-lowering agents - Google Patents

Liquid protein formulations containing viscosity-lowering agents

Info

Publication number
SG10201913950XA
SG10201913950XA SG10201913950XA SG10201913950XA SG10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA
Authority
SG
Singapore
Prior art keywords
formulations containing
lowering agents
protein formulations
liquid protein
containing viscosity
Prior art date
Application number
SG10201913950XA
Inventor
Alyssa Larson
Kevin Love
Alisha Weight
Alan Crane
Robert Langer
Alexander Klibanov
Original Assignee
Eagle Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics Inc filed Critical Eagle Biologics Inc
Publication of SG10201913950XA publication Critical patent/SG10201913950XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
SG10201913950XA 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents SG10201913950XA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361876621P 2013-09-11 2013-09-11
US201461940227P 2014-02-14 2014-02-14
US201461943197P 2014-02-21 2014-02-21
US201461946436P 2014-02-28 2014-02-28
US201461988005P 2014-05-02 2014-05-02
US201462008050P 2014-06-05 2014-06-05
US201462026497P 2014-07-18 2014-07-18
US201462030521P 2014-07-29 2014-07-29

Publications (1)

Publication Number Publication Date
SG10201913950XA true SG10201913950XA (en) 2020-03-30

Family

ID=51626611

Family Applications (6)

Application Number Title Priority Date Filing Date
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201913952TA SG10201913952TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201913950XA SG10201913950XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201913952TA SG10201913952TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Country Status (16)

Country Link
US (13) US9913905B2 (en)
EP (8) EP3043774B1 (en)
JP (10) JP6469113B2 (en)
KR (5) KR102651018B1 (en)
CN (7) CN105848636B (en)
AU (10) AU2014318725B2 (en)
CA (4) CA2923859C (en)
ES (5) ES2972527T3 (en)
HK (5) HK1225980A1 (en)
IL (4) IL312865A (en)
MX (6) MX2016003183A (en)
RU (2) RU2675824C2 (en)
SG (6) SG10201809401XA (en)
SI (4) SI3043774T1 (en)
WO (4) WO2015038818A2 (en)
ZA (4) ZA201601968B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2544719T (en) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37-binding molecules and immunoconjugates thereof
CN105999293B (en) 2011-04-01 2019-07-23 德彪发姆国际有限公司 CD37 binding molecule and its immunoconjugates
US20140348719A1 (en) * 2013-03-14 2014-11-27 Bureau Veritas Pharmaceutical compound stabilizing filter compositions and methods of making and using same
CA2923859C (en) 2013-09-11 2021-11-23 Arsia Therapeutics, Inc. Liquid protein formulations containing viscosity-lowering agents
MY189089A (en) * 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN106029064B (en) 2014-02-07 2018-08-14 艾克赛特赫拉制药有限责任公司 Therapeutic compounds and composition
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN106999510B (en) * 2014-10-01 2021-04-30 伊格尔生物制品有限公司 Polysaccharide and nucleic acid formulations containing viscosity reducing agents
CN108472361B (en) 2015-06-08 2022-12-27 德彪发姆国际有限公司 anti-CD 37 immunoconjugates and anti-CD 20 antibody compositions
CN107771076A (en) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 Use the axle binding antagonists of PD 1 and the method for Taxane treatment Locally Advanced or metastatic breast cancer
TWI797060B (en) * 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
DK3337502T3 (en) * 2015-08-19 2020-09-14 Astrazeneca Ab STABLE ANTI-IFNAR1 FORMULATION
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
TW201730211A (en) * 2015-10-30 2017-09-01 建南德克公司 Anti-Factor D antibodies and conjugates
JP7112327B2 (en) * 2015-12-29 2022-08-03 アウトルック セラピューティクス，インコーポレイティド Buffered Formulations of Bevacizumab
CN105699555B (en) * 2016-03-24 2018-09-11 中国标准化研究院 A kind of method for preparing liquid chromatography of 1-ethoxy-2-hydroxy-4-propenyl benzene
US10421811B2 (en) * 2016-04-25 2019-09-24 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies
EA201892524A1 (en) * 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания DNA monoclonal antibodies targeted at IL-6 and CD126
US10934568B2 (en) * 2016-06-07 2021-03-02 National Technology & Engineering Solutions Of Sandia, Llc Conversion of sugars to ionic liquids
JP6959327B2 (en) * 2016-08-18 2021-11-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Assay to determine the likelihood of protein self-association using concentration-dependent self-interacting nanoparticle spectroscopy
US11385201B1 (en) 2019-09-30 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274163B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11382976B1 (en) 2016-10-04 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274289B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11274137B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
AU2017347838B2 (en) * 2016-10-27 2023-04-27 Eisai R&D Management Co., Ltd. Composition comprising an anti-Αβ protofibril antibody and a beta-secretase BACE1 inhibitor for the treatment of Alzheimer's disease
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
CA3039796A1 (en) * 2016-11-02 2018-05-11 Polaris Group Formulations of pegylated arginine deiminase
WO2018152165A1 (en) * 2017-02-16 2018-08-23 Reform Biologics, Llc Excipient compounds for protein processing
JOP20190204A1 (en) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
CN110831621A (en) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 Stable liquid pharmaceutical composition
MA48461A (en) * 2017-04-28 2020-03-04 Amgen Inc EXCIPIENTS TO REDUCE THE VISCOSITY OF ANTIBODY FORMULATIONS AND FORMULATION COMPOSITIONS
KR20200003107A (en) 2017-05-02 2020-01-08 머크 샤프 앤드 돔 코포레이션 Preparation of Anti-LAG3 Antibodies, and Co-Formulations of Anti-LAG3 Antibodies and Anti-PD-1 Antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
WO2019004799A1 (en) * 2017-06-30 2019-01-03 한국과학기술원 Conjugate of vegf-grab protein and drug, and use thereof
BR112020003498A2 (en) * 2017-08-22 2020-08-25 Biogen Ma, Inc. pharmaceutical compositions and dosage regimens that contain anti-alpha (v) beta (6) antibodies
EP3678700B1 (en) * 2017-09-05 2024-06-19 Merck Sharp & Dohme LLC Compounds for reducing the viscosity of biological formulations
CA3082070A1 (en) * 2017-11-07 2019-05-16 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
EP3709974A4 (en) * 2017-11-17 2021-08-04 President And Fellows Of Harvard College Ionic liquids for internal delivery
CN108096185A (en) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 A kind of Insulin Aspart and preparation method thereof
JP7256816B2 (en) * 2018-03-07 2023-04-12 コメラ ライフ サイエンシズ，インコーポレイテッド Excipient compounds for protein formulations
CA3097061A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
US11730698B2 (en) * 2018-07-19 2023-08-22 Celltrion Inc. Stable liquid pharmaceutical preparation
US20210346598A1 (en) * 2018-10-19 2021-11-11 Hoffmann-La Roche Inc. Microdosing
MX2021005910A (en) * 2018-11-21 2021-08-16 Regeneron Pharma High concentration protein formulation.
US11058770B1 (en) * 2019-01-24 2021-07-13 United States Of America As Represented By The Secretary Of The Air Force Ultrastable antibody ionic liquids
EP3927729A4 (en) 2019-02-18 2023-10-11 Eli Lilly and Company Therapeutic antibody formulation
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
EP4031106A1 (en) * 2019-09-17 2022-07-27 Merck Patent GmbH Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
EP4208160A1 (en) * 2020-09-01 2023-07-12 I2O Therapeutics, Inc. Ionic liquid formulations for treating diabetes
CN113249358B (en) * 2021-05-14 2022-10-14 天津大学 Method for regulating and controlling crystal form of lysozyme by using ionic liquid
US20240277840A1 (en) * 2021-07-01 2024-08-22 Upkara, Inc. Superconcentrated formulations of bioactive agents
CN115350330B (en) * 2022-09-01 2023-10-20 北京化工大学 Application of electronegative micromolecule regulated surface in protein differential adhesion
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190082A (en) 1877-04-24 Improvement in apparatus for cooling liquids
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (en) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogous process for the preparation of adrenocorticotropically active nonadecapeptide amides or acid addition salts or complex compounds thereof.
BE757195A (en) 1969-10-07 1971-03-16 Century Disposable Devices SYRINGE FOR INJECTING A FRESHLY PREPARED MIXTURE OF POWDER AND LIQUID
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
ATE171185T1 (en) 1985-03-15 1998-10-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (en) * 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd Erythropoietin hypodermic or intramuscular administration agent
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69419721T2 (en) 1993-01-12 2000-04-27 Biogen, Inc. RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (en) 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
DE4344824C1 (en) 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (en) * 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ Prefilled syringe and package thereof
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19617369A1 (en) 1996-04-30 1997-11-06 Immuno Ag Storage-stable fibrinogen preparations
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6808706B1 (en) 1997-10-15 2004-10-26 Asaki Kasei Pharma Corporation Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
US6451617B1 (en) 1997-10-22 2002-09-17 Chugai Seiyaku Kabushiki Kaisha Method of screening TGF-β inhibitory substances
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (en) 1999-06-11 2003-04-11 Solutions BIOMATERIAL BASED ON AN INSOLUBILIZED DEXTRAN DERIVATIVE AND A GROWTH FACTOR, METHOD FOR PREPARING SAME AND ITS APPLICATIONS
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (en) 1999-07-29 2003-09-10 Wilhelm A. Keller Cartridge discharge device with actuator for dynamic mixers
BRPI0017437B8 (en) 1999-10-04 2021-05-25 Chiron Corp stabilized pharmaceutical composition containing IL-2 polypeptide, method of increasing stability of interleukin-2 in a pharmaceutical composition, and a dry form of the composition
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP2116265B1 (en) 2000-10-12 2020-12-23 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002051470A2 (en) 2000-11-30 2002-07-04 Biovalve Technologies, Inc. Injection systems
NZ525888A (en) 2000-12-01 2006-04-28 Max Planck Gesellschaft RNA interference mediating small RNA molecules
WO2002092014A2 (en) 2001-05-16 2002-11-21 Biomarin Pharmaceutical Inc. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP1440043A1 (en) 2001-08-02 2004-07-28 3M Innovative Properties Company Abrasive particles and methods of making and using the same
JP4167820B2 (en) 2001-10-19 2008-10-22 アルインコ株式会社 Deck plate traveling cart
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
ATE392886T1 (en) * 2002-07-31 2008-05-15 Alza Corp INJECTABLE DEPOSIT COMPOSITIONS AND USE THEREOF
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL2405015T3 (en) 2003-03-05 2016-09-30 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CA2520775A1 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
AU2004230482A1 (en) 2003-04-15 2004-10-28 Biozyme Laboratories, Ltd Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US7993872B2 (en) 2003-06-18 2011-08-09 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
CN1206344C (en) 2003-07-28 2005-06-15 中国海洋大学 Method for producing fucan sulfatase by means of bacteria
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
EP2662390B1 (en) 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
DE602004027396D1 (en) 2004-11-25 2010-07-08 Chr Hansen As Process for the preparation of a carmine scrub
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
CN101111264A (en) * 2005-01-28 2008-01-23 惠氏公司 Stabilized liquid polypeptide formulations
CN103271083B (en) 2005-10-07 2017-08-11 阿拉巴马大学 Multi-functional ionic liquid compositions
CN100416002C (en) * 2005-10-26 2008-09-03 曲新华 Sewage recycling apparatus
SG153832A1 (en) 2005-12-20 2009-07-29 Bristol Myers Squibb Co Stable protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN1823768A (en) 2006-01-09 2006-08-30 徐新盛 Cimetidine freeze dried composition
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (en) 2006-02-04 2007-08-09 Degussa Gmbh Titanium dioxide and polycarboxylate ether-containing dispersion
ITMI20061030A1 (en) 2006-05-26 2007-11-27 Altergon Sa NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
CU23526B6 (en) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech METHOD FOR MORFOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
CN101689450B (en) 2007-07-20 2012-07-18 应用材料公司 RF choke for gas delivery to an RF driven electrode in a plasma processing apparatus
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
US8383114B2 (en) 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
CN103705507A (en) 2007-10-16 2014-04-09 环状药物公司 Manufacture, compositions and uses of coagulationfactor viia modulator
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
BRPI0819714A8 (en) 2007-11-30 2016-05-10 Abbott Lab PROTEIN FORMULATIONS AND PRODUCTION METHODS THEREOF
EP2234636A4 (en) 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc Stabilized formulations of peptides and proteins
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US20120251615A1 (en) * 2008-01-18 2012-10-04 Horst Kief Agent for intra-articular injection
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) * 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
PE20120359A1 (en) 2009-03-06 2012-04-13 Genentech Inc FORMULATION WITH ANTIBODY
RU2560701C2 (en) 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Stable compositions with high concentrations of proteins of human antibodies against tnf-alpha
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
KR101882408B1 (en) 2009-05-20 2018-07-27 세키스이 메디칼 가부시키가이샤 Blood coagulation time prolonging agent
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20130236448A1 (en) * 2009-08-04 2013-09-12 F. Hoffmann-La Roche Ag (Roche Glycart Ag) Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
IN2012DN03219A (en) 2009-09-17 2015-10-23 Baxter Healthcare Sa
US8895242B2 (en) 2009-10-20 2014-11-25 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN102770157B (en) 2009-11-20 2017-05-17 拜康有限公司 Formulations of antibody
WO2011069037A2 (en) * 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
DK2510096T4 (en) 2009-12-10 2018-05-14 Univ Iowa State Res Found Inc NUMBER EFFECTOR-MEDIATED DNA MODIFICATION
WO2011083110A2 (en) 2010-01-08 2011-07-14 Chanel Parfums Beaute Use of at least one extract of flowers of camellia japonica alba plena for moisturizing the skin
EP2531218B1 (en) 2010-02-04 2018-12-12 CSL Behring AG Immunoglobulin preparation
JP2013520476A (en) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス Stable antibody-containing composition
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
AU2011227335B2 (en) 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
EP2552482A2 (en) 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
CN101851267A (en) 2010-04-22 2010-10-06 江南大学 Antibody protective agent and application thereof
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
RS56210B1 (en) * 2010-05-14 2017-11-30 Amgen Inc High concentration antibody formulations
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
CN105854016A (en) * 2010-11-11 2016-08-17 艾伯维生物技术有限公司 Improved high concentration anti-TNF[alpha] antibody liquid formulations
US8936827B2 (en) 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
CA2832560A1 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
US20140023655A1 (en) 2011-04-07 2014-01-23 Glaxosmithkline Llc Formulations with reduced viscosity
EP4257165A3 (en) 2011-05-12 2023-11-15 Bayer Healthcare LLC Fluid injection system having various systems for controlling an injection procedure
RU2485133C2 (en) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Protein-polypeptide complex possessing tissue-specific regenerative-reparative and rejuvenating action on skin tissue, method for preparing it, and pharmaceutical composition thereof
CN102349895B (en) 2011-09-28 2013-04-10 海南良方医药有限公司 Cimetidine composition for injection and preparation method thereof
EP2771301B1 (en) 2011-10-25 2017-12-20 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104023748B (en) 2011-10-28 2018-03-02 诚信生物公司 Protein formulation containing amino acid
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
EP2854760B1 (en) 2012-05-25 2018-10-17 Novartis AG Aqueous pharmaceutical composition containing a biologic therapeutic agent and l-arginine derivative and an injection including the composition
TR201806812T4 (en) 2012-05-25 2018-06-21 Charpentier Emmanuelle Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modification.
MA37777B1 (en) 2012-06-21 2017-07-31 Ucb Pharma Sa Pharmaceutical preparation
PL3494997T3 (en) 2012-07-25 2020-04-30 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
MX2015001678A (en) 2012-08-09 2015-08-14 Roche Glycart Ag Asgpr antibodies and uses thereof.
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (en) 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
WO2014160083A1 (en) 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
CA2923859C (en) 2013-09-11 2021-11-23 Arsia Therapeutics, Inc. Liquid protein formulations containing viscosity-lowering agents
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN106999510B (en) * 2014-10-01 2021-04-30 伊格尔生物制品有限公司 Polysaccharide and nucleic acid formulations containing viscosity reducing agents
US10812184B1 (en) 2019-04-03 2020-10-20 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Signal analysis systems and methods

Also Published As

Publication number Publication date
KR20220123552A (en) 2022-09-07
JP2018199735A (en) 2018-12-20
JP6941137B2 (en) 2021-09-29
AU2014318637A1 (en) 2016-04-07
CN111202711A (en) 2020-05-29
MX2016003183A (en) 2016-11-14
RU2675824C2 (en) 2018-12-25
RU2016113283A (en) 2017-10-17
EP4403187A2 (en) 2024-07-24
CN110559435B (en) 2023-10-20
US10821184B2 (en) 2020-11-03
ES2837629T3 (en) 2021-07-01
RU2016113283A3 (en) 2018-07-27
CA2924069A1 (en) 2015-03-19
IL244433B (en) 2020-07-30
US20240285766A1 (en) 2024-08-29
WO2015038811A2 (en) 2015-03-19
EP3808338A1 (en) 2021-04-21
US20180177875A1 (en) 2018-06-28
NZ717918A (en) 2021-05-28
US20150071925A1 (en) 2015-03-12
US10646571B2 (en) 2020-05-12
EP3043776B1 (en) 2024-01-03
SI3043774T1 (en) 2021-01-29
AU2020202407A1 (en) 2020-05-07
KR20160054009A (en) 2016-05-13
CA2923843C (en) 2022-07-12
AU2020202407B2 (en) 2023-07-13
ES2972527T3 (en) 2024-06-13
HK1225981A1 (en) 2017-09-22
US20210085792A1 (en) 2021-03-25
JP6564512B2 (en) 2019-08-21
WO2015038782A1 (en) 2015-03-19
CA2923844C (en) 2022-07-26
US20150071920A1 (en) 2015-03-12
JP6515105B2 (en) 2019-05-15
CN110559435A (en) 2019-12-13
US9925263B2 (en) 2018-03-27
IL275388B1 (en) 2024-06-01
US20210038718A1 (en) 2021-02-11
IL244430B (en) 2020-06-30
JP2016530318A (en) 2016-09-29
CN105705139A (en) 2016-06-22
EP3043772B1 (en) 2023-07-19
AU2014318725B2 (en) 2020-01-23
IL312865A (en) 2024-07-01
JP6463581B2 (en) 2019-02-06
CN105705139B (en) 2019-07-26
SG10201913952TA (en) 2020-03-30
JP2020203956A (en) 2020-12-24
NZ756401A (en) 2021-05-28
SI3043772T1 (en) 2023-10-30
SG11201601730TA (en) 2016-04-28
EP3791862C0 (en) 2024-05-29
CA2923844A1 (en) 2015-03-19
EP3043776A1 (en) 2016-07-20
RU2019140607A (en) 2020-05-29
US10179172B2 (en) 2019-01-15
ES2980815T3 (en) 2024-10-03
AU2020202240B2 (en) 2023-02-09
JP2016530321A (en) 2016-09-29
US20150071921A1 (en) 2015-03-12
JP6774484B2 (en) 2020-10-21
HK1225982A1 (en) 2017-09-22
SG10201809401XA (en) 2018-11-29
US9913905B2 (en) 2018-03-13
AU2014318691B2 (en) 2020-01-23
AU2020202408A1 (en) 2020-05-07
EP3791862B1 (en) 2024-05-29
EP4272763A3 (en) 2024-02-14
US20180177876A1 (en) 2018-06-28
SG11201601728YA (en) 2016-04-28
CN105722501B (en) 2019-07-26
KR102295633B1 (en) 2021-08-30
US20150071922A1 (en) 2015-03-12
AU2023229619A1 (en) 2023-10-05
SG10201806539XA (en) 2018-08-30
AU2014318696A1 (en) 2016-04-07
MX2021012049A (en) 2021-11-03
US20180085463A1 (en) 2018-03-29
US20240181063A1 (en) 2024-06-06
RU2019140607A3 (en) 2022-04-18
MX2016003182A (en) 2017-03-31
CN105722501A (en) 2016-06-29
CN105722500B (en) 2019-08-30
AU2014318637B2 (en) 2020-01-23
AU2014318691A1 (en) 2016-04-07
ZA201801669B (en) 2021-07-28
JP6412575B2 (en) 2018-10-24
US11819550B2 (en) 2023-11-21
MX2021005907A (en) 2021-06-23
BR112016005309A2 (en) 2017-08-01
CA2923859A1 (en) 2015-03-19
EP3043774A2 (en) 2016-07-20
CA2923843A1 (en) 2015-03-19
AU2014318725A1 (en) 2016-04-07
JP2019142985A (en) 2019-08-29
ZA201601968B (en) 2018-07-25
KR102651018B1 (en) 2024-03-27
CN110496099A (en) 2019-11-26
AU2014318725A2 (en) 2019-02-14
US9833513B2 (en) 2017-12-05
JP2019056006A (en) 2019-04-11
EP3043775A2 (en) 2016-07-20
NZ717944A (en) 2021-06-25
JP2019073563A (en) 2019-05-16
RU2016113385A (en) 2017-10-16
AU2023251546A1 (en) 2023-11-16
KR102435648B1 (en) 2022-08-25
ES2841134T3 (en) 2021-07-07
BR112016005309A8 (en) 2021-06-22
JP6840797B2 (en) 2021-03-10
WO2015038818A3 (en) 2015-07-16
JP2019178176A (en) 2019-10-17
JP2016534141A (en) 2016-11-04
KR20210110396A (en) 2021-09-07
JP6469113B2 (en) 2019-02-13
NZ756260A (en) 2021-06-25
ZA201802108B (en) 2022-04-28
CN110496099B (en) 2022-06-21
WO2015038811A3 (en) 2015-07-23
US10849977B2 (en) 2020-12-01
KR20160055243A (en) 2016-05-17
US11986526B2 (en) 2024-05-21
CN105848636A (en) 2016-08-10
WO2015038777A1 (en) 2015-03-19
IL244430A0 (en) 2016-04-21
JP7214697B2 (en) 2023-01-30
US10821183B2 (en) 2020-11-03
EP3043775B1 (en) 2020-11-04
HK1225979A1 (en) 2017-09-22
MX2021012048A (en) 2021-11-03
CA2924069C (en) 2021-11-02
KR20240042200A (en) 2024-04-01
JP6768858B2 (en) 2020-10-14
EP3043774B1 (en) 2020-11-04
WO2015038818A2 (en) 2015-03-19
JP2023021352A (en) 2023-02-10
EP4272763A2 (en) 2023-11-08
JP2016530319A (en) 2016-09-29
SI3043775T1 (en) 2021-01-29
IL244433A0 (en) 2016-04-21
ES2959451T3 (en) 2024-02-26
US20210030877A1 (en) 2021-02-04
EP3791862A1 (en) 2021-03-17
IL275388B2 (en) 2024-10-01
HK1226309A1 (en) 2017-09-29
CN105722500A (en) 2016-06-29
HK1225980A1 (en) 2017-09-22
AU2023200941A1 (en) 2023-03-30
CN105848636B (en) 2020-02-21
KR102289825B1 (en) 2021-08-17
CN111202711B (en) 2022-06-21
AU2014318696B2 (en) 2020-01-23
CA2923859C (en) 2021-11-23
AU2020202408B2 (en) 2023-09-21
ZA202102906B (en) 2023-12-20
SI3043776T1 (en) 2024-03-29
EP3043772A1 (en) 2016-07-20
AU2020202240A1 (en) 2020-04-23
IL275388A (en) 2020-07-30
US20180153997A1 (en) 2018-06-07
RU2710542C2 (en) 2019-12-27
MX2021012050A (en) 2021-11-03

Similar Documents

Publication Publication Date Title
IL275388A (en) Liquid protein formulations containing viscosity-lowering agents
HK1222557A1 (en) Stable liquid formulation of amg 416 (velcalcetide) amg 416(velcalcetide)
SG11201508564QA (en) Cleaning liquid composition
EP2955579A4 (en) Liquid developing agent
HUE039180T2 (en) Liquid detergent composition
ZA201507331B (en) Liquid cleaning composition
EP3041352B8 (en) Cleaning liquid
IL241040A0 (en) Raceadotril liquid compositions
GB2532663B (en) Liquid mouthwash
HK1220366A1 (en) Protein formulations
SG11201506298YA (en) Liquid container
EP2830607A4 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
EP2997039A4 (en) Stabilized liquid formulations containing receptors
PL2865740T3 (en) Liquid scouring composition
EP2997114A4 (en) Ionic liquid composition
GB201315537D0 (en) Liquid mixer
HK1179466A2 (en) Liquid container